Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Bradycardia associated with remdesivir treatment in coronavirus disease 2019 patients: A propensity score-matched analysis

Mohammed et al., Medicine, doi:10.1097/MD.0000000000044501, Oct 2025
https://c19early.org/mohammed2.html
Mortality 67% Improvement Relative Risk Hospitalization time -117% Bradycardia -58% Remdesivir  Mohammed et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? PSM retrospective 202 patients in the USA (March 2020 - March 2021) Longer hospitalization with remdesivir (p<0.000001) c19early.org Mohammed et al., Medicine, October 2025 Favorsremdesivir Favorscontrol 0 0.5 1 1.5 2+
Retrospective 645 hospitalized COVID-19 patients in the USA showing higher incidence of bradycardia and longer hospital stay with remdesivir treatment. Mortality was lower, however the reported p-value of <0.001 is not plausible.
With 1 death in the remdesivir group and 3 in the control group across 101 matched pairs, McNemar’s two-sided p (with continuity correction, as specified) ranges from ~0.48 (if the single remdesivir death is paired with a control death; b = 2, c = 0) to ~0.62 (if there is no overlap; b = 3, c = 1).
Moreover, the PSM excluded 63 of 64 deaths in the treatment group - the matched group is not representative of the population.
We also note that the bradycardia and hospitalization time results are similar in the unmatched and matched groups, however the mortality result changes from ~3x higher to ~3x lower.
Gérard, Zhou, Wu, Kamo, Choi, Kim show increased risk of acute kidney injury, Leo, Briciu, Muntean, Petrov show increased risk of liver injury, and Negru, Cheng, Mohammed show increased risk of cardiac disorders with remdesivir.
Remdesivir efficacy disappears with longer followup. Mixed-effects meta-regression of efficacy as a function of followup duration across all remdesivir studies shows decreasing efficacy with longer followup14. This may reflect antiviral efficacy being offset by serious adverse effects of treatment.
Followup duration (days) Mortality efficacy Remdesivir efficacy decreases with longer followup 0 15 30 45 60 75 90 105 -25% 0% 25% 50% c19early.org October 2025 mixed-effects meta-regression slope -0.58 [95% CI -0.92 to -0.24] p=0.00089
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments15. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
risk of death, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 101 (1.0%), control 3 of 101 (3.0%), NNT 51, propensity score matching.
hospitalization time, 117.5% higher, relative time 2.17, p < 0.001, treatment mean 13.7 (±12.8) n=101, control mean 6.3 (±5.5) n=101, propensity score matching.
bradycardia, 58.1% higher, RR 1.58, p = 0.01, treatment 49 of 101 (48.5%), control 31 of 101 (30.7%), propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mohammed et al., 3 Oct 2025, retrospective, USA, peer-reviewed, mean age 57.0, 12 authors, study period 1 March, 2020 - 31 March, 2021. Contact: singh@unlv.edu.
Bradycardia associated with remdesivir treatment in coronavirus disease 2019 patients: A propensity score-matched analysis
BS a , Salman Mohammed, MD Justin Bauzon, PhD Kavita Batra, BA Celica Cosme, BS a , Kim Inciong, MD Elli Tian, MD a , Fadi Azar, M d , Kevin Lee, MD d Nazanin Houshmand, MD d Uyen Pham, MD d Ariyon Schreiber, MD Aditi Singh
Medicine, doi:10.1097/md.0000000000044501
Remdesivir is an antiviral drug recommended for the treatment of COVID-19. The therapeutic benefits of remdesivir remain under investigation, with further literature emerging regarding its cardiac side-effect profile. The objective of this study was to investigate the association of remdesivir with bradycardia using a propensity score-matched analysis. Secondary outcomes included assessing in-patient mortality and hospital length of stay following remdesivir treatment for COVID-19. A single-institution retrospective study investigating treatment with and without remdesivir in 645 patients admitted for COVID-19 management was performed. Following treatment with remdesivir, patients were analyzed for episodes of bradycardia, defined in this study as 2 consecutive episodes of a heart rate <60 beats per minute. Matched cohorts were generated after controlling for potential confounders associated with remdesivir exposure. Subsequently, a propensity score-matched analysis was conducted to minimize selection bias and to account for the characteristics between the 2 comparison groups. In a sample of 645 COVID-19 patients, 58% were in the treatment group (Remdesivir+) and 42% were in the control group (Remdesivir-). 59% were males with a mean age of 57 ± 14.5 years. After propensity score matching, the remdesivir + group had a higher incidence of bradycardia (48.5% vs 30.7%, P = .028). The remdesivir + group was found to have a lower rate of in-patient mortality (1.0% vs 3.0% P < .001) and longer in-patient length of stay (13.7 vs 6.3 days, P < .001) compared to the remdesivir-group. Patients with COVID-19 had a greater prevalence of bradycardia following treatment with remdesivir. For these patients, remdesivir reduced in-patient mortality compared with untreated COVID-19 patients.
Author contributions Conceptualization: Salman Mohammed, Justin Bauzon
References
Ahmadi, Karimi, Abdollahi, Kabir, Modeling for prediction of mortality based on past medical history in hospitalized COVID-19 Patients: a secondary analysis, Can J Infect Dis Med Microbiol
Al-Jammali, Al-Zakhari, Sheets, Mahtani, Stefanishina et al., Bradyarrhythmia after remdesivir administration in SARS-CoV-2: a review of literature and meta-analysis of observational studies in epidemiology, Cardiol Res
Aleem, Kothadia, Remdesivir
Anderson, Bach, Baldwin, Hospital length of stay for patients with severe COVID-19: implications for Remdesivir's value, PharmacoEcon Open
Attena, Albani, Maraolo, Remdesivir-induced bradycardia in COVID-19: a single center prospective study, Circ Arrhythm Electrophysiol
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharm Stat
Bauzon, Murphy, Wahi-Gururaj, Using macros in microsoft excel to facilitate cleaning of research data, J Community Hosp Intern Med Perspect
Beigel, Tomashek, Dodd, ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 -final report, N Engl J Med
Bistrovic, Lucijanic, Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot study, J Med Virol
Bistrovic, Manola, Lucijanic, Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre, Postgrad Med J
Brunetti, Poliseno, Bottalico, Safety and heart rate changes in Covid-19 patients treated with Remdesivir, Int J Infect Dis
Buczek, Azar, Bauzon, Batra, Murphy et al., The Data Error Criteria (DEC) for retrospective studies: development and preliminary application, J Investig Med
Capoferri, Osthoff, Egli, Stoeckle, Bassetti, Relative bradycardia in patients with COVID-19, Clin Microbiol Infect
Chalkias, Pantazopoulos, Papagiannakis, Sinus bradycardia is associated with poor outcome in critically ill patients with COVID-19 due to the B.1.1.7 Lineage, Toxicol Rep
Chokkalingam, Hayden, Goldman, Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States, JAMA Netw Open
Cohen, Statistical Power Analysis for the Behavioral Sciences
Devlin, Skrobik, Gélinas, Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU, Crit Care Med
Diaz, Christensen, Pusch, Remdesivir and mortality in patients with COVID-19, Clin Infect Dis
Douedi, Mararenko, Alshami, COVID-19 induced bradyarrhythmia and relative bradycardia: an overview, J Arrhythm
Filtz, Carandina, Fasiello, Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism, Intern Emerg Med
Garrido, Kelley, Paris, Methods for constructing and assessing propensity scores, Health Serv Res
Grundeis, Ansems, Dahms, Remdesivir for the treatment of COVID-19, Cochrane Database Syst Rev
Gubitosa, Kakar, Gerula, Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review, JACC Case Rep
Hafeez, Grossman, Sinus bradycardia
Haghjoo, Golipra, Kheirkhah, Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: results of a multicenter national survey, Int J Clin Pract
Hajimoradi, Kashani, Dastan, Remdesivir associated sinus bradycardia in patients with COVID-19: a prospective longitudinal study, Front Pharmacol
Hung, Wang, Hung, Chen, An updated meta-analysis of pooled incidence of remdesivir-associated bradycardia, J Med Virol
Ishisaka, Aikawa, Malik, Kampaktsis, Briasoulis et al., Association of Remdesivir use with bradycardia: a systematic review and meta-analysis, J Med Virol
Izcovich, Siemieniuk, Bartoszko, Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials, BMJ Open
Kumar, Arcuri, Chaudhuri, A novel study on SARS-COV-2 virus associated bradycardia as a predictor of mortality-retrospective multicenter analysis, Clin Cardiol
Leite, Practical Propensity Score Methods Using R
Liu, Pan, Yin, Li, Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis, Virol J
Lovekirat, Boparai, Ceaser, 108: remdesivir and cardiac arrhythmia in COVID-19, Crit Care Med
Lucijanic, Bistrovic, Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients, Clin Microbiol Infect
Mcmillan, Zureikat, Hogg, A propensity scorematched analysis of robotic vs open pancreatoduodenectomy on incidence of pancreatic fistula, JAMA Surg
Mozaffari, Chandak, Zhang, Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort, Clin Infect Dis
Nabati, Parsaee, Potential cardiotoxic effects of remdesivir on cardiovascular system: a literature review, Cardiovasc Toxicol
Nagamine, Randhawa, Nishimura, Characteristics of bradyarrhythmia in patients with COVID-19: systematic scoping review, Pacing Clin Electrophysiol
Ohl, Miller, Lund, Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19, JAMA Netw Open
Olender, Walunas, Martinez, Remdesivir versus standardof-care for severe coronavirus disease 2019 infection: an analysis of 28-day mortality, Open Forum Infect Dis
Pallotto, Suardi, Gabbuti, Esperti, Mecocci et al., Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19), J Med Virol
Pantazopoulos, Mavrovounis, Dimeas, Remdesivirinduced bradycardia is not associated with worse outcome in patients with COVID-19: a retrospective analysis, Am J Cardiovasc Drugs
Saffar, Nabati, Saffar, Yazdani, Investigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: a historical cohort study, BMC Cardiovasc Disord
Schreiber, Bauzon, Batra, Clinical characteristics and implications of bradycardia in COVID-19 patients treated with remdesivir: a single-center retrospective cohort study, Clin Drug Investig
Sekhon, Grieve, A matching method for improving covariate balance in cost-effectiveness analyses, Health Econ
Shaikh, Sarfaraz, Rahim, Hussain, Shah et al., Effect of Remdesivir on mortality and length of stay in hospitalized COVID-19 patients: a single center study, Pak J Med Sci
Steele, Gerlach, Elefritz, Sadaqat, Phelps, Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis, Int J Crit Illn Inj Sci
Tajarernmuang, Trongtrakul, Chaiwong, Bradycardia and heart rate fluctuation are associated with a prolonged intensive care unit stay in patients with severe COVID-19, Medicina
Touafchia, Bagheri, Carrié, Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns, Clin Microbiol Infect
Umeh, Giberson, Kumar, Aseri, Barve, A multicenter retrospective analysis on the etiology of bradycardia in COVID-19 patients, Cureus
Uusalo, Valtonen, Järvisalo, Hemodynamic and respiratory effects of dexmedetomidine sedation in critically ill Covid-19 patients: a retrospective cohort study, Acta Anaesthesiol Scand
Valojerdi, Janani, A brief guide to propensity score analysis, Med J Islam Repub Iran
Veronese, Gennaro, Frallonardo, Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis, Sci Rep
Zhang, Kim, Lonjon, Zhu, Balance diagnostics after propensity score matching, Ann. Transl. Med
DOI record: { "DOI": "10.1097/md.0000000000044501", "ISSN": [ "0025-7974", "1536-5964" ], "URL": "http://dx.doi.org/10.1097/MD.0000000000044501", "abstract": "<jats:p>Remdesivir is an antiviral drug recommended for the treatment of COVID-19. The therapeutic benefits of remdesivir remain under investigation, with further literature emerging regarding its cardiac side-effect profile. The objective of this study was to investigate the association of remdesivir with bradycardia using a propensity score-matched analysis. Secondary outcomes included assessing in-patient mortality and hospital length of stay following remdesivir treatment for COVID-19. A single-institution retrospective study investigating treatment with and without remdesivir in 645 patients admitted for COVID-19 management was performed. Following treatment with remdesivir, patients were analyzed for episodes of bradycardia, defined in this study as 2 consecutive episodes of a heart rate &lt;60 beats per minute. Matched cohorts were generated after controlling for potential confounders associated with remdesivir exposure. Subsequently, a propensity score-matched analysis was conducted to minimize selection bias and to account for the characteristics between the 2 comparison groups. In a sample of 645 COVID-19 patients, 58% were in the treatment group (Remdesivir+) and 42% were in the control group (Remdesivir-). 59% were males with a mean age of 57 ± 14.5 years. After propensity score matching, the remdesivir + group had a higher incidence of bradycardia (48.5% vs 30.7%, <jats:italic toggle=\"yes\">P</jats:italic> = .028). The remdesivir + group was found to have a lower rate of in-patient mortality (1.0% vs 3.0% <jats:italic toggle=\"yes\">P</jats:italic> &lt; .001) and longer in-patient length of stay (13.7 vs 6.3 days, <jats:italic toggle=\"yes\">P</jats:italic> &lt; .001) compared to the remdesivir- group. Patients with COVID-19 had a greater prevalence of bradycardia following treatment with remdesivir. For these patients, remdesivir reduced in-patient mortality compared with untreated COVID-19 patients.</jats:p>", "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "value": "2024-10-21" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "value": "2025-08-26" } ], "author": [ { "ORCID": "https://orcid.org/0000-0002-8881-5559", "affiliation": [ { "name": "Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas (UNLV), NV" } ], "authenticated-orcid": false, "family": "Mohammed", "given": "Salman", "sequence": "first" }, { "affiliation": [ { "name": "Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas (UNLV), NV" }, { "name": "Department of General Surgery, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH" } ], "family": "Bauzon", "given": "Justin", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medical Education and Office of Research, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV" } ], "family": "Batra", "given": "Kavita", "sequence": "additional" }, { "affiliation": [ { "name": "Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas (UNLV), NV" } ], "family": "Cosme", "given": "Celica", "sequence": "additional" }, { "affiliation": [ { "name": "Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas (UNLV), NV" } ], "family": "Inciong", "given": "Kim", "sequence": "additional" }, { "affiliation": [ { "name": "Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas (UNLV), NV" } ], "family": "Tian", "given": "Elli", "sequence": "additional" }, { "affiliation": [ { "name": "Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas (UNLV), NV" } ], "family": "Azar", "given": "Fadi", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV." } ], "family": "Lee", "given": "Kevin", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV." } ], "family": "Houshmand", "given": "Nazanin", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV." } ], "family": "Pham", "given": "Uyen", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV." } ], "family": "Schreiber", "given": "Ariyon", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-7247-2213", "affiliation": [ { "name": "Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV." } ], "authenticated-orcid": false, "family": "Singh", "given": "Aditi", "sequence": "additional" } ], "container-title": "Medicine", "content-domain": { "crossmark-restriction": true, "domain": [ "lww.com", "ovid.com" ] }, "created": { "date-parts": [ [ 2025, 10, 6 ] ], "date-time": "2025-10-06T20:05:53Z", "timestamp": 1759781153000 }, "deposited": { "date-parts": [ [ 2025, 10, 6 ] ], "date-time": "2025-10-06T20:05:58Z", "timestamp": 1759781158000 }, "indexed": { "date-parts": [ [ 2025, 10, 7 ] ], "date-time": "2025-10-07T01:07:10Z", "timestamp": 1759799230354, "version": "build-2065373602" }, "is-referenced-by-count": 0, "issue": "40", "issued": { "date-parts": [ [ 2025, 10, 3 ] ] }, "journal-issue": { "issue": "40", "published-print": { "date-parts": [ [ 2025 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "unspecified", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 10, 3 ] ], "date-time": "2025-10-03T00:00:00Z", "timestamp": 1759449600000 } } ], "link": [ { "URL": "https://journals.lww.com/10.1097/MD.0000000000044501", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "276", "original-title": [], "page": "e44501", "prefix": "10.1097", "published": { "date-parts": [ [ 2025, 10, 3 ] ] }, "published-print": { "date-parts": [ [ 2025, 10, 3 ] ] }, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "reference": [ { "DOI": "10.1056/NEJMoa2007764", "article-title": "Remdesivir for the treatment of Covid-19 – final report.", "author": "Beigel", "doi-asserted-by": "crossref", "first-page": "1813", "journal-title": "N Engl J Med", "key": "R1-20251006", "volume": "383", "year": "2020" }, { "article-title": "Remdesivir for the treatment of COVID-19.", "author": "Grundeis", "first-page": "CD014962", "journal-title": "Cochrane Database Syst Rev", "key": "R3-20251006", "volume": "1", "year": "2023" }, { "DOI": "10.1016/S0140-6736(22)00519-0", "article-title": "Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.", "doi-asserted-by": "crossref", "first-page": "1941", "journal-title": "Lancet", "key": "R4-20251006", "volume": "399", "year": "2022" }, { "DOI": "10.14740/cr1377", "article-title": "Bradyarrhythmia after remdesivir administration in SARS-CoV-2: a review of literature and meta-analysis of observational studies in epidemiology.", "author": "Al-Jammali", "doi-asserted-by": "crossref", "first-page": "135", "journal-title": "Cardiol Res", "key": "R5-20251006", "volume": "13", "year": "2022" }, { "DOI": "10.1007/s40261-022-01187-x", "article-title": "Clinical characteristics and implications of bradycardia in COVID-19 patients treated with remdesivir: a single-center retrospective cohort study.", "author": "Schreiber", "doi-asserted-by": "crossref", "first-page": "763", "journal-title": "Clin Drug Investig", "key": "R6-20251006", "volume": "42", "year": "2022" }, { "DOI": "10.1002/joa3.12578", "article-title": "COVID-19 induced bradyarrhythmia and relative bradycardia: an overview.", "author": "Douedi", "doi-asserted-by": "crossref", "first-page": "888", "journal-title": "J Arrhythm", "key": "R7-20251006", "volume": "37", "year": "2021" }, { "DOI": "10.1016/j.jaccas.2020.08.025", "article-title": "Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review.", "author": "Gubitosa", "doi-asserted-by": "crossref", "first-page": "2260", "journal-title": "JACC Case Rep", "key": "R8-20251006", "volume": "2", "year": "2020" }, { "DOI": "10.1016/j.toxrep.2021.07.004", "article-title": "Sinus bradycardia is associated with poor outcome in critically ill patients with COVID-19 due to the B.1.1.7 Lineage.", "author": "Chalkias", "doi-asserted-by": "crossref", "first-page": "1394", "journal-title": "Toxicol Rep", "key": "R9-20251006", "volume": "8", "year": "2021" }, { "DOI": "10.1002/clc.23622", "article-title": "A novel study on SARS-COV-2 virus associated bradycardia as a predictor of mortality-retrospective multicenter analysis.", "author": "Kumar", "doi-asserted-by": "crossref", "first-page": "857", "journal-title": "Clin Cardiol", "key": "R10-20251006", "volume": "44", "year": "2021" }, { "DOI": "10.4103/ijciis.ijciis_57_24", "article-title": "Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.", "author": "Steele", "doi-asserted-by": "crossref", "first-page": "203", "journal-title": "Int J Crit Illn Inj Sci", "key": "R11-20251006", "volume": "14", "year": "2024" }, { "article-title": "A multicenter retrospective analysis on the etiology of bradycardia in COVID-19 patients.", "author": "Umeh", "first-page": "e21294", "journal-title": "Cureus", "key": "R12-20251006", "volume": "14", "year": "2022" }, { "DOI": "10.1161/CIRCEP.121.009811", "article-title": "Remdesivir-induced bradycardia in COVID-19: a single center prospective study.", "author": "Attena", "doi-asserted-by": "crossref", "first-page": "e009811", "journal-title": "Circ Arrhythm Electrophysiol", "key": "R13-20251006", "volume": "14", "year": "2021" }, { "DOI": "10.1002/jmv.27177", "article-title": "Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot study.", "author": "Bistrovic", "doi-asserted-by": "crossref", "first-page": "5724", "journal-title": "J Med Virol", "key": "R16-20251006", "volume": "93", "year": "2021" }, { "DOI": "10.1136/bmjopen-2020-048502", "article-title": "Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.", "author": "Izcovich", "doi-asserted-by": "crossref", "first-page": "e048502", "journal-title": "BMJ Open", "key": "R17-20251006", "volume": "12", "year": "2022" }, { "DOI": "10.1186/s12985-021-01604-1", "article-title": "Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis.", "author": "Liu", "doi-asserted-by": "crossref", "first-page": "157", "journal-title": "Virol J", "key": "R18-20251006", "volume": "18", "year": "2021" }, { "DOI": "10.1007/s41669-020-00243-6", "article-title": "Hospital length of stay for patients with severe COVID-19: implications for Remdesivir’s value.", "author": "Anderson", "doi-asserted-by": "crossref", "first-page": "129", "journal-title": "PharmacoEcon Open", "key": "R19-20251006", "volume": "5", "year": "2021" }, { "DOI": "10.1097/CCM.0000000000003299", "article-title": "Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU.", "author": "Devlin", "doi-asserted-by": "crossref", "first-page": "e825", "journal-title": "Crit Care Med", "key": "R20-20251006", "volume": "46", "year": "2018" }, { "DOI": "10.1111/aas.13970", "article-title": "Hemodynamic and respiratory effects of dexmedetomidine sedation in critically ill Covid-19 patients: a retrospective cohort study.", "author": "Uusalo", "doi-asserted-by": "crossref", "first-page": "1447", "journal-title": "Acta Anaesthesiol Scand", "key": "R21-20251006", "volume": "65", "year": "2021" }, { "DOI": "10.1080/20009666.2021.1954282", "article-title": "Using macros in microsoft excel to facilitate cleaning of research data.", "author": "Bauzon", "doi-asserted-by": "crossref", "first-page": "653", "journal-title": "J Community Hosp Intern Med Perspect", "key": "R22-20251006", "volume": "11", "year": "2021" }, { "DOI": "10.1177/10815589231151437", "article-title": "The Data Error Criteria (DEC) for retrospective studies: development and preliminary application.", "author": "Buczek", "doi-asserted-by": "crossref", "first-page": "448", "journal-title": "J Investig Med", "key": "R23-20251006", "volume": "71", "year": "2023" }, { "DOI": "10.1002/pst.433", "article-title": "Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.", "author": "Austin", "doi-asserted-by": "crossref", "first-page": "150", "journal-title": "Pharm Stat", "key": "R25-20251006", "volume": "10", "year": "2011" }, { "DOI": "10.1093/cid/ciab875", "article-title": "Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort.", "author": "Mozaffari", "doi-asserted-by": "crossref", "first-page": "e450", "journal-title": "Clin Infect Dis", "key": "R26-20251006", "volume": "75", "year": "2022" }, { "DOI": "10.1002/hec.1748", "article-title": "A matching method for improving covariate balance in cost-effectiveness analyses.", "author": "Sekhon", "doi-asserted-by": "crossref", "first-page": "695", "journal-title": "Health Econ", "key": "R27-20251006", "volume": "21", "year": "2012" }, { "DOI": "10.1111/1475-6773.12182", "article-title": "Methods for constructing and assessing propensity scores.", "author": "Garrido", "doi-asserted-by": "crossref", "first-page": "1701", "journal-title": "Health Serv Res", "key": "R29-20251006", "volume": "49", "year": "2014" }, { "DOI": "10.1001/jamasurg.2016.4755", "article-title": "A propensity score-matched analysis of robotic vs open pancreatoduodenectomy on incidence of pancreatic fistula.", "author": "McMillan", "doi-asserted-by": "crossref", "first-page": "327", "journal-title": "JAMA Surg", "key": "R30-20251006", "volume": "152", "year": "2017" }, { "DOI": "10.21037/atm.2018.12.10", "article-title": "Balance diagnostics after propensity score matching.", "author": "Zhang", "doi-asserted-by": "crossref", "first-page": "16", "journal-title": "Ann. Transl. Med", "key": "R31-20251006", "volume": "7", "year": "2019" }, { "DOI": "10.1016/j.cmi.2021.12.017", "article-title": "Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients.", "author": "Lucijanic", "doi-asserted-by": "crossref", "first-page": "619", "journal-title": "Clin Microbiol Infect", "key": "R32-20251006", "volume": "28", "year": "2022" }, { "DOI": "10.3389/fphar.2022.1107198", "article-title": "Remdesivir associated sinus bradycardia in patients with COVID-19: a prospective longitudinal study.", "author": "Hajimoradi", "doi-asserted-by": "crossref", "first-page": "1107198", "journal-title": "Front Pharmacol", "key": "R33-20251006", "volume": "13", "year": "2023" }, { "DOI": "10.1007/s40256-022-00547-4", "article-title": "Remdesivir-induced bradycardia is not associated with worse outcome in patients with COVID-19: a retrospective analysis.", "author": "Pantazopoulos", "doi-asserted-by": "crossref", "first-page": "705", "journal-title": "Am J Cardiovasc Drugs", "key": "R34-20251006", "volume": "22", "year": "2022" }, { "DOI": "10.1136/postgradmedj-2021-141079", "article-title": "Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre.", "author": "Bistrovic", "doi-asserted-by": "crossref", "first-page": "501", "journal-title": "Postgrad Med J", "key": "R35-20251006", "volume": "98", "year": "2022" }, { "DOI": "10.1002/jmv.29584", "article-title": "An updated meta-analysis of pooled incidence of remdesivir-associated bradycardia.", "author": "Hung", "doi-asserted-by": "crossref", "first-page": "e29584", "journal-title": "J Med Virol", "key": "R36-20251006", "volume": "96", "year": "2024" }, { "DOI": "10.1002/jmv.29018", "article-title": "Association of Remdesivir use with bradycardia: a systematic review and meta-analysis.", "author": "Ishisaka", "doi-asserted-by": "crossref", "first-page": "e29018", "journal-title": "J Med Virol", "key": "R37-20251006", "volume": "95", "year": "2023" }, { "DOI": "10.1002/jmv.26898", "article-title": "Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).", "author": "Pallotto", "doi-asserted-by": "crossref", "first-page": "2631", "journal-title": "J Med Virol", "key": "R38-20251006", "volume": "93", "year": "2021" }, { "DOI": "10.1007/s11739-022-03168-6", "article-title": "Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism [published online ahead of print, 2022 Dec 21].", "author": "Filtz", "doi-asserted-by": "crossref", "first-page": "359", "journal-title": "Intern Emerg Med", "key": "R39-20251006", "volume": "18", "year": "2022" }, { "DOI": "10.1016/j.ijid.2021.09.036", "article-title": "Safety and heart rate changes in Covid-19 patients treated with Remdesivir.", "author": "Brunetti", "doi-asserted-by": "crossref", "first-page": "254", "journal-title": "Int J Infect Dis", "key": "R41-20251006", "volume": "112", "year": "2021" }, { "DOI": "10.1007/s12012-021-09703-9", "article-title": "Potential cardiotoxic effects of remdesivir on cardiovascular system: a literature review.", "author": "Nabati", "doi-asserted-by": "crossref", "first-page": "268", "journal-title": "Cardiovasc Toxicol", "key": "R42-20251006", "volume": "22", "year": "2022" }, { "DOI": "10.1016/j.cmi.2020.08.013", "article-title": "Relative bradycardia in patients with COVID-19.", "author": "Capoferri", "doi-asserted-by": "crossref", "first-page": "295", "journal-title": "Clin Microbiol Infect", "key": "R43-20251006", "volume": "27", "year": "2021" }, { "DOI": "10.1186/s12872-024-04380-2", "article-title": "Investigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: a historical cohort study.", "author": "Saffar", "doi-asserted-by": "crossref", "first-page": "700", "journal-title": "BMC Cardiovasc Disord", "key": "R44-20251006", "volume": "24", "year": "2024" }, { "DOI": "10.1111/ijcp.14182", "article-title": "Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: results of a multicenter national survey.", "author": "Haghjoo", "doi-asserted-by": "crossref", "first-page": "e14182", "journal-title": "Int J Clin Pract", "key": "R45-20251006", "volume": "75", "year": "2021" }, { "DOI": "10.1038/s41598-024-59957-w", "article-title": "Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.", "author": "Veronese", "doi-asserted-by": "crossref", "first-page": "9303", "journal-title": "Sci Rep", "key": "R46-20251006", "volume": "14", "year": "2024" }, { "DOI": "10.3390/medicina58070950", "article-title": "Bradycardia and heart rate fluctuation are associated with a prolonged intensive care unit stay in patients with severe COVID-19.", "author": "Tajarernmuang", "doi-asserted-by": "crossref", "first-page": "950", "journal-title": "Medicina (Kaunas)", "key": "R47-20251006", "volume": "58", "year": "2022" }, { "DOI": "10.1111/pace.14466", "article-title": "Characteristics of bradyarrhythmia in patients with COVID-19: systematic scoping review.", "author": "Nagamine", "doi-asserted-by": "crossref", "first-page": "556", "journal-title": "Pacing Clin Electrophysiol", "key": "R48-20251006", "volume": "45", "year": "2022" }, { "DOI": "10.1001/jamanetworkopen.2022.44505", "article-title": "Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States.", "author": "Chokkalingam", "doi-asserted-by": "crossref", "first-page": "e2244505", "journal-title": "JAMA Netw Open", "key": "R49-20251006", "volume": "5", "year": "2022" }, { "DOI": "10.1093/ofid/ofab278", "article-title": "Remdesivir versus standard-of-care for severe coronavirus disease 2019 infection: an analysis of 28-day mortality.", "author": "Olender", "doi-asserted-by": "crossref", "first-page": "ofab278", "journal-title": "Open Forum Infect Dis", "key": "R50-20251006", "volume": "8", "year": "2021" }, { "DOI": "10.1001/jamanetworkopen.2021.14741", "article-title": "Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19.", "author": "Ohl", "doi-asserted-by": "crossref", "first-page": "e2114741", "journal-title": "JAMA Netw Open", "key": "R51-20251006", "volume": "4", "year": "2021" }, { "DOI": "10.1093/cid/ciab698", "article-title": "Remdesivir and mortality in patients with COVID-19.", "author": "Diaz", "doi-asserted-by": "crossref", "first-page": "1812", "journal-title": "Clin Infect Dis", "key": "R52-20251006", "volume": "74", "year": "2022" }, { "DOI": "10.1016/j.cmi.2021.02.013", "article-title": "Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.", "author": "Touafchia", "doi-asserted-by": "crossref", "first-page": "791.E5", "journal-title": "Clin Microbiol Infect", "key": "R53-20251006", "volume": "25", "year": "2021" }, { "DOI": "10.1097/01.ccm.0000806756.21865.b4", "article-title": "108: remdesivir and cardiac arrhythmia in COVID-19.", "author": "Lovekirat", "doi-asserted-by": "crossref", "first-page": "37", "journal-title": "Crit Care Med", "key": "R54-20251006", "volume": "50", "year": "2022" }, { "article-title": "A brief guide to propensity score analysis.", "author": "Ebrahim Valojerdi", "first-page": "122", "journal-title": "Med J Islam Repub Iran", "key": "R55-20251006", "volume": "32", "year": "2018" }, { "DOI": "10.1155/2024/3256108", "article-title": "Modeling for prediction of mortality based on past medical history in hospitalized COVID-19 Patients: a secondary analysis.", "author": "Ahmadi", "doi-asserted-by": "crossref", "first-page": "3256108", "journal-title": "Can J Infect Dis Med Microbiol", "key": "R56-20251006", "volume": "2024", "year": "2024" }, { "article-title": "Effect of Remdesivir on mortality and length of stay in hospitalized COVID-19 patients: a single center study.", "author": "Shaikh", "first-page": "405", "journal-title": "Pak J Med Sci", "key": "R57-20251006", "volume": "38", "year": "2022" } ], "reference-count": 51, "references-count": 51, "relation": {}, "resource": { "primary": { "URL": "https://journals.lww.com/10.1097/MD.0000000000044501" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Bradycardia associated with remdesivir treatment in coronavirus disease 2019 patients: A propensity score-matched analysis", "type": "journal-article", "update-policy": "https://doi.org/10.1097/lww.0000000000001000", "volume": "104" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit